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Abstract
Polycystic ovary syndrome (PCOS) is a common endocrine disease in women of 
childbearing age. Many heterogeneous clinical manifestations of PCOS, including 
hyperandrogenism, obesity, insulin resistance, hirsutism, acne, chronic anovulation 
and infertility, seriously affected the quality of life of women worldwide and made 
it difficult to clearly demonstrate the specific pathophysiology. In recent years, 
large-scale studies have shown that non-coding RNAs (ncRNAs) play an important 
role in the regulation of ovarian functions, which did not have the ability to encode 
proteins and could regulate hormone synthesis and germ cell development, differ-
entiation, and apoptosis by silencing transposable elements and regulating coding 
genes. A number of researches by whole transcriptome sequencing of polycystic 
ovaries (PCO) from PCOS patients or PCOS model animals found that the abnor-
mal expressions of many ncRNAs were involved in the regulation of ovarian dys-
functions of PCOS, including the development of oocytes, the microenvironment 
of follicular fluid, and the proliferation, differentiation, and apoptosis of granulosa 
cells. The present review focused on the roles of ncRNAs in the PCO of PCOS, in 
order to provide a theoretical basis for further understanding of the molecular 
mechanisms of PCO formation in PCOS.
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1. Introduction
Polycystic ovary syndrome (PCOS) is an endocrine and reproductive disease in 
women that often occurs during the childbearing years [1]. PCOS is closely related 
to metabolic syndrome, and has become an increasingly serious public health prob-
lem worldwide, these patients have an increased risk of endometrial cancer, type 2 
diabetes, and cardiovascular disease. The clinical characteristics of PCOS women 
show heterogeneity, include excessive androgen, infertility, obesity, anovulation, 
irregular menstruation, polycystic ovaries (PCO), hairy and recurrent miscarriage, 
insulin resistance and abnormal blood lipids [2].
Anovulatory infertility of PCOS patients accounts for more than 75%, and 
the spontaneous abortion rate of them in early pregnancy is 30–50% [3, 4]. 
Ovulation failure (such as ovulation or anovulation) is the main clinical features of 
PCOS. There are a large number of small follicles in the bilateral ovaries of PCOS 
patients, which can not grow into dominant follicle, suggesting the occurrence of 
follicular dysplasia [5]. The processes of ovarian follicular development and atresia 
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are a complex and delicate. However, ovulatory dysfunction in PCOS women is 
related to various factors such as abnormalities in proliferation and apoptosis of 
granule cells (GCs) and in follicular development and atresia. As is well-known 
that GCs are involved in the normal development and maturation of follicles. 
Some studies have found that the proliferation rate of GCs in PCOS patients is 
significantly higher, and the apoptotic rate is significantly lower [6, 7] suggesting 
that abnormalities in the proliferation and apoptosis of GCs may be a pathogenic 
mechanism of ovarian dysfunction of PCOS.
Due to the complexity of the etiology of PCOS, its specific pathophysiology 
has not yet been fully elucidated. More and more researches are currently being 
conducted to analyze the gene expression profiling of PCOS at the mRNA and 
protein levels, in order to explore its molecular mechanisms. PCOS is caused by 
the imbalance of multiple gene pathways [8]. The candidate genes are involved 
in sex hormone synthesis, insulin synthesis, chronic inflammatory factors, lipid 
metabolism, cell proliferation and apoptosis [8]. With the advancement of RNA 
sequencing technologies, many researchers have discovered that non-coding RNA 
(ncRNA, which refers to a class of RNA without open reading frame and can not 
translate into proteins) is involved in the regulation of numerous cell signaling 
pathways and biological processes for life activities, such as cell development, 
differentiation, apoptosis and hormone synthesis, and the occurrence and devel-
opment of diseases [9].
Most of the human genome is transcribed into various ncRNAs, MicroRNA 
(miRNA) and long-chain non-coding RNAs (lncRNA) are hotspots for studying 
novel biomarkers and therapeutic targets in related diseases in recent years, such 
as cancer [10], diabetes [11] and PCOS [9]. Recent studies have shown that both 
miRNA and lncRNA play an important role in the pathogenesis of PCOS [9, 12]. 
miRNA and lncRNA can directly or indirectly affect the normal physiological func-
tions of the ovaries, include the growth and development of follicles and oocytes 
[9, 12]. Moreover, ovarian dysfunction in PCOS seriously affects the reproductive 
capacity in reproductive women, but its specific molecular mechanism is not yet 
known. This chapter focuses on the roles of several ncRNAs in PCOS ovaries in 
recent years, which will help to further elucidate its pathogenesis and to discover 
new therapeutic targets.
2. ncRNA
ncRNAs as enzyme, regulatory signal, molecular sink, ligand, organizer of 
cellular structures, potential hormone and scaffold of molecular interactions, can 
play an important role in cell physiology and abnormal biological processes, such 
as nuclear transport, transcriptional regulation of genes, protein degradation, 
genomic imprinting and X chromosome silencing [13].
2.1 miRNAs
miRNAs are 21–23 nucleotides in length and widely found in eukaryotes, which 
can predict post-transcriptional regulation of at least half of the human transcrip-
tome [14–16]. Mature miRNA is formed by removing and processing a longer pri-
mary transcript through a series of nucleases [17–19]. The main function of miRNAs 
is silencing or degrading the expressions of target genes at the post-transcriptional 
level by forming an RNA-induced silencing complex [20]. Abnormal expressions of 
miRNAs are associated with insulin resistance [21, 22], diabetes [11, 22, 23], inflam-
mation [20, 23] and various cancer formations [10]. The expression profiles of some 
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miRNAs in ovarian various cells and follicular fluids of PCOS patients exist signifi-
cant differences, which had been involved in the occurrence and development 
of PCOS by affecting the post-transcriptional regulation of the target  
genesw [9, 12, 24].
2.2 lncRNAs
lncRNAs are a class of non-coding RNAs transcripts longer than 200 nucleo-
tides in length, which produced by 4–9% of the sequence in mammalian genome 
[25, 26]. lncRNAs play critical roles in various human biological processes, such as 
chromatin modification, cell differentiation, proliferation and apoptosis, trans-
lational and post-translational regulation. Moreover, the abnormally expressed 
lncRNAs are involved in the occurrence and development of a variety of human 
diseases [27]. In recent years, more and more evidence has shown that lncRNAs 
are abnormally expressed in ovarian cumulus cells and/or GCs of PCOS patients 
[9, 28, 29]. These lncRNAs may be involved in ovarian steroid production, steroid 
receptor activity and IR, and future affect ovarian cell development, proliferation 
and apoptosis, which in turn leads to the occurrence of ovarian dysfunction of 
PCOS [28, 29].
3. PCO
PCO is one of the diagnostic indicators and symptoms for PCOS, which imaged 
the ovaries with ultrasound showing ≥12 follicles (each follicle is 2–9 mm in 
diameter) on one or both sides, and/or an ovarian volume ≥10 ml [5]. During the 
development and maturation of ovarian follicles, the oocyte interconnected and 
interdependent with surrounding GCs. The development of an oocyte requires 
GCs to provide nutrients, corresponding hormones and growth regulators [30, 31]. 
Abnormal interactions between GCs and oocytes are a possible cause of ovarian 
follicular dysplasia in PCOS [32]. Some vitro fertilization studies found that PCOS 
patients have a lower rate of implantation than normal women [33–35]. Microarray 
analysis indicated that abnormal endocrine and metabolism affect gene expression 
of oocytes in PCOS ovaries [36].
Moreover, ovarian follicular fluid is a fluid that fills the follicular cavity and 
surrounds cumulus cells. Follicular fluid is rich in substances such as hormones, 
growth factors, anti-apoptotic antibodies, various proteins, peptides, amino acids 
and nucleotides. Studies have confirmed that these substances are closely related 
to female reproductive system diseases, embryo quality and in vitro fertilization 
outcomes [37]. Therefore, the homeostasis of the microenvironment of follicular 
fluid directly affects follicular development and oocytes quality.
It is well known that insulin resistance and hyperinsulinemia play an impor-
tant role in the pathophysiology of PCOS. Studies have found that most of PCOS 
patients with varying degrees of IR and compensatory hyperinsulinemia, including 
ovarian IR [38]. Ovarian GCs in PCOS patients are impaired by insulin-dependent 
glucose metabolism [38, 39]. Damaged glucose metabolism reduces the energy sup-
ply to GCs and oocytes, and thus hinders the proliferation of GCs and the develop-
ment of oocytes [38, 39]. Therefore, GCs dysfunction is contributed to abnormal 
ovarian function in PCOS, including anovulation. Moreover, excessive apoptosis of 
cumulus GCs directly causes follicular dysplasia in PCOS, which are correlated with 
changes in ncRNAs expression profiles in follicular fluid. The abnormal expressions 
of ncRNAs from the ovaries of PCOS may contribute to its occurrence and develop-
ment [9, 12, 40].
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4. Effects of ncRNAs on ovarian dysfunction of PCOS
With the development of RNA sequencing technologies, many researchers have 
carried out miRNA or lncRNA sequencing studies on the ovaries of PCOS, in order 
to detect the molecular mechanisms of ovarian dysfunction. Studies have shown that 
compared with control rats, there are 129 miRNAs (49 miRNAs are up-regulated, 80 
miRNAs are down-regulated) and 158 lncRNAs (114 lncRNAs are up-regulated, 44 
lncRNAs are down-regulated) by deep-sequencing of ovaries tissue from letrozole-
induced PCOS rats [41, 42]. Gene ontology (GO) and Kyoto encyclopedia of genes 
and genomes (KEG) Genes pathway analyzed and predicted that the differentially 
expressed ncRNAs in PCOS ovaries may be associated with abnormal ovarian GCs 
proliferation, apoptosis and steroidogenesis and ovarian insulin resistance [41, 42].
4.1 Roles of ncRNAs in the proliferation and apoptosis of GCs
4.1.1 miR-141-3p
In the ovaries of PCOS rat model, the expression of miR-141-3p is significantly 
decreased, which can target to death-associated protein kinase 1 (DAPK1) and 
mitogen-activated protein kinase 1 (MAPK1) signaling pathway to inhibit apoptosis 
of GCs, or regulate mitochondria-mediated apoptosis through phosphatidylinositol 
3 kinase/protein kinase B (PI3K/Akt) and extracellular protein kinase (ERK) signal-
ing pathways, and thus suppressing cell growth, promoting cell apoptosis, and 
further leading to the development of PCOS [41].
4.1.2 miR-483-5p
miR-483-5p is the most abundant known miRNA in human ovarian follicular 
fluid [43]. miR-483-5p is highly expressed in cumulus granulosa cells and follicular 
fluid of PCOS patients [44]. In PCOS cumulus cells, high concentrations of miR-
483-5p hinders the expressions of Notch3 and MAPK3 protein by binding to the 
3′UTR terminus of their mRNA, thereby blocking the Notch signaling pathway 
and the MAPK signaling pathway (the two pathways play an important role in cell 
proliferation, differentiation and apoptosis), which inhibits the proliferation and 
differentiation of cumulus GCs and promoted the apoptosis of GCs [44].
4.1.3 LncRNA CD36-005
lncRNA CD36-005 is a transcript encoding the fatty acid transporter CD36 gene, 
which may be involved in cell growth, development, transport, and metabolism 
by bioinformatics analysis [42, 45]. lncRNA CD36-005 is expressed in rat ova-
ries, and its expression level is related to the estrous cycle, which indicates that it 
plays a role in animal reproductive activities [45]. Moreover, the study found that 
lncRNA CD36-005 and CD36 were highly expressed in the ovaries of PCOS rats by 
high-throughput sequencing and qRT-PCR verification. lncRNA CD36-005 signifi-
cantly inhibits the proliferation of GCs by reducing the viability and the S phase 
of the cell cycle, which may be involved in the pathogenesis of PCOS [42].
4.2 Roles of ncRNAs in ovarian steroidogenesis
4.2.1 miR-320
miR-320 is closely related to PCOS, especially in the process of follicular 
development [46, 47]. miR-320 can regulate the translation of its target genes by 
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post-transcriptional regulation, thereby improving the levels of steroid hormones. 
miR-320 was down-regulated in cumulus GCs from PCOS ovaries [48], and its 
expression in follicular fluid was controversial [49]. miR-320 deficiency not only 
impairs the expression of the steroid synthase CYP11A1 and CYP19A1, but also 
enhances the steroidogenesis in CGs by directly regulating the RUNX2/CYP11AI cas-
cade in the 3′UTR of Runx2, indicating that the cascade are a possible mechanism for 
the lack of estrogen synthesis in GCs of PCOS patients. In addition, miR-320 can target 
transcriptional factors E2F1 and steroidogenic factor-1 (SF-1) to inhibit the prolifera-
tion of GCs, and promote the synthesis of testosterone and progesterone [47].
4.2.2 LncRNA HCG26
lncRNA HCG26 is mainly distributed in the nucleus of ovarian GCs, which is highly 
expressed in PCOS patients [29]. HCG26 knockout can promote aromatase gene expres-
sion and estradiol synthesis, but can not affect the levels of androstenedione and follicle 
stimulating hormone, suggesting lncRNA HCG26 is involved in abnormal ovarian 
steroidogenic synthesis [50]. Moreover, the study also found that lncRNA HCG26 defi-
ciency inhibits the proliferation of GCs and its expression correlated with the number 
of PCOS ovarian follicles, suggesting that lncRNA HCG26 may affect the proliferation 
of GCs and contributes to the formation of polycystic ovary morphology [29].
4.3 Roles of ncRNAs in ovarian insulin resistance
4.3.1 miR-92
Down-regulation of miR-92a/b expression in PCOS patients is associated 
with insulin resistance, hyperinsulinemia and hyperandrogenism [24], which can 
increase the expression of its target gene IRS-2, which activates the insulin signal-
ing pathway in the ovaries of PCOS patients, thereby leading to be involved in the 
process of insulin resistance and hyperinsulinemia [24, 29].
4.3.2 miR-145
miR-145 overexpression in GCs of PCOS patients inhibits the target gene IRS1 
and MAPK/ERK signaling pathways, and promotes the activity of PI3K/Akt signaling 
pathway through negative feedback, thereby improving IR in PCOS patients [7, 24, 50].
5. Conclusions
PCOS is a chronic disease that affects the patients throughout their lives. 
However, there is currently no gene that is recognized as the determinant of the 
pathogenesis of PCOS. Although the differential expression of ncRNAs in the 
ovaries from PCOS are involving in ovarian steroidogenesis, insulin resistance, 
cell proliferation and apoptosis and affect follicular development by regulating the 
expression of corresponding target genes at the post-transcriptional level, there are 
still many ncRNAs and the specific mechanism of their action in ovarian function 
of PCOS have not been discovered. Moreover, the roles and mechanisms of lncRNAs 
in PCOS have just been carried out, and the focus is on the study of lncRNA in 
peripheral blood of the patients or animal models, that in ovarian tissue is limited. 
The interactions between ncRNAs in PCOS have not been reported, such as miRNA-
miRNA, lncRNA-lncRNA, and miRNA-lncRNA. Solving these problems will be 
contribution to further understand the etiology and pathogenesis of PCOS.
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A. Appendices
PCOS polycystic ovary syndrome
ncRNAs non-coding RNA
PCO polycystic ovary
GCs granule cells
lncRNA long-chain non-coding RNAs
GO gene ontology
KEGG Kyoto encyclopedia of genes and genomes
DAPK1 death-associated protein kinase 1
MAP K1 mitogen-activated protein kinase 1
PI3K/Akt phosphatidylinositol 3 kinase/protein kinase B
ERK extracellular protein kinase
SF-1 steroidogenic factor-1
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